Brufen Retard
PreclinicalSmall molecule
Brufen Retard is one of 50 small molecule programs targeting Post Operative Pain. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
64 competitors in Post Operative Pain
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Duragesic
CCephalon
Approved
Journavx
Vertex PharmaceuticalsApproved
Tylenol
KKenvue Brands
Approved
Ketalar
AAultman Health Foundation
Approved
Oxycontin
PProtega
Approved
Suboxone
IIndivior Inc.
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Cyklokapron
JJ Molner
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Post Operative Pain1 trial
Effect of Ibuprofen Sustained Release on Intraoperative and Postoperative Pain in Mandibular Molars
Unknown status·—·N/A·NCT05053009·48 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Brufen Retard. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Manchester